Company Overview of Angiochem Inc.
Angiochem Inc. is a clinical-stage biotechnology company developing drugs to treat brain diseases and brain-related disorders. Its products are used to treat oncology, pain, type II diabetes and obesity, Parkinson's disease, neurodegenerative and metabolic diseases, pain, and other central nervous system related disorders. The company develops products based on its engineered peptide compound (EPiC) technology. Angiochem Inc. was founded in 2003 and is based in Montreal, Canada.
201 President-Kennedy Avenue
Montreal, QC H2X 3Y7
Founded in 2003
Key Executives for Angiochem Inc.
Vice President of Development
Director of Corporate Development
Compensation as of Fiscal Year 2014.
Angiochem Inc. Key Developments
Angiochem Inc. Presents at Boston CEO Conference, Jun-04-2014 01:45 PM
Jun 2 14
Angiochem Inc. Presents at Boston CEO Conference, Jun-04-2014 01:45 PM. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, Massachusetts, United States. Speakers: Jean-Paul Castaigne, Chairman, Chief Executive Officer and President.
Angiochem Demonstrates Peptide Antibody Conjugate That Successfully Crosses the Blood Brain Barrier and Increases Survival in HER-2 Positive Brain Tumors
Dec 16 13
Angiochem announced that its peptide-antibody conjugate, ANG4043 successfully crosses the BBB, reduces tumor size and significantly increases survival in mice with intracranial HER2-positive brain tumors. These results underscore the potential for development of novel antitumor therapeutics for neuro-oncology indications. The data presentation revealed that the company's technology has been successfully applied to monoclonal antibodies (mAbs) for creation of brain-penetrant antibody conjugates of anti-Human Epidermal Growth Factor Receptor 2 (HER2). Angiochem researchers described the ANG4043 preclinical results, including: In vivo, in mice that were implanted intracranially with HER2+ human breast tumor cells (BT-474), it was observed: ANG4043 crosses the BBB and reaches the tumor using near-infrared imaging, where a strong signal is observed in brain following IV administration of fluorescent ANG4043, but not of fluorescent anti-HER2. Reduction in tumor size correlating with increased survival. In vitro, ANG4043 binding affinity for HER2 receptor and anti-proliferative properties were similar to the native, unconjugated mAb.
Angiochem Inc. Presents at 2013 Therapeutic Area Partnerships Conference, Nov-19-2013 01:30 PM
Nov 15 13
Angiochem Inc. Presents at 2013 Therapeutic Area Partnerships Conference, Nov-19-2013 01:30 PM. Venue: One Avenue De Lafayette, Boston, MA 02111, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|